Amgen 145 Study Shows No Difference In Risk Of Death In Aranesp-Treated Patients
This article was originally published in The Pink Sheet Daily
Outcome could help to stabilize the use of erythropoiesis-stimulating agents in anemia patients in the oncology setting.
You may also be interested in...
Labeling for Amgen’s Aranesp and Epogen and Johnson & Johnson’s Procrit updated March 9 to include a black box warning on risk of mortality.
Letter follows release of data in patients receiving darbepoetin alfa who have anemia that is not due to concurrent chemotherapy, an off-label use.
Patients with chronic kidney disease, when treated with a more aggressive dose of Procrit, had a higher risk but no incremental improvement in quality of life.